Skip to content
Research Article Open access CC BY 4.0

Metformin as an Adjuvant Therapy Attenuates Dextran Sulphate Sodium-induced Acute Colitis in Rats

Rania M. Magadmi, Fahad H. Aljahdali, Mustafa Alsawy, Ahmed S. Ali, Fatemah O. Kamel

Journal of Pharmaceutical Research International · pp. 84–96 · Published 30 Jun 2020

10.9734/jpri/2020/v32i1030496

Abstract

Aims: In numerous cases, patients with inflammatory bowel diseases (IBDs) are refractory to standard treatment. Sirolimus (SIR) and tacrolimus (TAC) are immunosuppressant drugs with encouraging outcomes. However, they have side effects causing limitations in their use. Metformin (MET), which is an antidiabetic drug, has promising anti-inflammatory effects. Thus, this study aimed to validate the effect of the concomitant administration of MET and SIR or TAC in the management of experimentally induced colitis. Study Design: Dextran sulphate (DSS) induced colitis model was used. Methodology: Colitis was induced by administering 5% DSS in water twice daily via oral gavage for 9 days. MET 200 mg/kg alone or in combination with SIR 1 mg/kg or TAC 1 mg/kg was started on day 7 and was continuously administered for 12 days. Then, samples of distal colon tissues were collected for histopathological and immunohistochemistry staining. Then, the pro-inflammatory cytokine, tumour necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, and IL-17A levels in tissue homogenates were measured. Results: MET, SIR or TAC significantly attenuated the effect of DSS and the levels of all pro-inflammatory cytokines. Moreover, adding MET reinforces the effect of SIR and TAC. Conclusion: MET had a strong anti-inflammatory effect against DSS-induced colitis. Hence, it could be a promising adjuvant therapy in the management of IBDs. The effect was mediated, in part, by inhibiting NF-κB activation. However, the results of this study must be further validated and translated to clinical implications.

Metformin immunosuppressant inflammatory bowel disease ulcerative colitis NF-κB.

References (18)

  1. 1 Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [DOI]
  2. 2 Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases [DOI]
  3. 3 Cdx1 and Cdx2 expression during intestinal development [DOI]
  4. 4 Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance [DOI]
  5. 5 Use of sirolimus (rapamycin) to treat refractory Crohn’s disease [DOI]
  6. 6 Classical and recent advances in the treatment of inflammatory bowel diseases [DOI]
  7. 7 Dextran Sulfate Sodium (DSS)-Induced Acute Colitis in the Rat [DOI]
  8. 8 Management of Side Effects of Sirolimus Therapy [DOI]
  9. 9 NF-kB transcription factor: a key player in the generation of immune response
  10. 10 Effects of steroid treatment on activation of nuclear factor κB in patients with inflammatory bowel disease [DOI]
  11. 11 The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children [DOI]
  12. 12 Small bowel length in inflammatory bowel disease [DOI]
  13. 13 mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile [DOI]
  14. 14 Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice [DOI]
  15. 15 Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review [DOI]
  16. 16 Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification [DOI]
  17. 17 Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats [DOI]
  18. 18 Metformin exerts anti‑inflammatory effects on mouse colon smooth muscle cells in�vitro [DOI]

Cited by 1

1 citation reported by external sources — individual citing-article records aren't available to list yet.

Related research

Article metrics

Real usage data collected on this platform.

11

Page views

0

PDF downloads

1

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.